Core Viewpoint - BeiGene (06160.HK) will report its unaudited financial results for the third quarter ending September 30, 2025, on November 6, 2025, after the trading hours of the Hong Kong Stock Exchange [1] Financial Reporting - The financial results will be prepared in accordance with U.S. Generally Accepted Accounting Principles and applicable rules of the U.S. Securities and Exchange Commission [1] - The company's audit committee will review and approve the financial results on the same day, November 6, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 2025年第三季度財務業績公佈日期及審計委員會行動通告 百濟神州有限公司（「本公司」）謹此公佈，本公司將於2025年11月6日（星期四） （即香港聯交所交易時間之後）報告其根據美國公認會計原則及美國證券交易委員 會適用規則編製的截至2025年9月30日止第三季度的未經審核財務業績。本公司 董事會審計委員會將於2025年11月6日（香港時間）審閱及批准2025年第三季度的 財務業績。 財務業績發佈後，本公司將於美國東部時間2025年11月6日（星期四）上午八時正 （即香港時間2025年11月6日（星期四）下午九時正）舉行電話會議。 電話會議將以網路直播方式進行，網絡直播鏈接可從本公司網站的投資者關係頁 面訪問，網址為 https://ir.beonemedicines.com , https ...

Core Insights - The attitude of foreign capital towards Chinese medical assets has dramatically reversed within a year, shifting from a neutral to a positive outlook on the biotechnology sector in China [1][3][7] Group 1: Market Sentiment Shift - Morgan Stanley's report titled "China Biotech: Innovation Dawn" indicates that China's biotechnology sector is now viewed as a critical part of the global new drug supply chain, with projected pharmaceutical revenues reaching $34 billion by 2030 and $220 billion by 2040 [1][3] - The number of foreign institutions conducting research on Chinese biotech companies has surged, with notable firms like State Street Bank and BlackRock showing increased interest [1][2] - The collective buying actions of foreign investors, such as JPMorgan and Citigroup, reflect a significant shift in sentiment towards Chinese innovative drug companies [2][5] Group 2: Investment Dynamics - The efficiency of converting research interest into actual holdings is evident, as seen in the stock price surge of WuXi AppTec, which rose by 6.52% due to increased foreign investment [2] - Major foreign investors have increased their holdings in key Chinese biotech firms, indicating a trend of strategic accumulation among top foreign capital [5][6] - The report highlights that foreign capital is now viewing specific sectors in China as essential assets in the global technology race, with over 90% of U.S. investors expressing plans to increase exposure to Chinese stocks, particularly in biotechnology [6][7] Group 3: Industry Evolution - The narrative surrounding China's pharmaceutical industry has shifted from being cost-driven to innovation-driven, acknowledging the significant advancements in the sector [3][4] - Morgan Stanley and Goldman Sachs both emphasize the growing recognition of China's innovative capabilities in biotechnology, with expectations that several leading biotech firms will reach breakeven by 2025-2026 [4][8] - The report outlines that the Chinese biotech sector is becoming a key player in filling the revenue gaps created by patent expirations in multinational corporations (MNCs), with an estimated $115 billion revenue loss due to patent cliffs by 2035 [8][10] Group 4: Future Projections - By 2040, China's share of FDA-approved drugs is expected to rise from 5% to 35%, with a projected global sales figure exceeding $1.22 trillion even in the most pessimistic scenarios [25][27] - The report anticipates that the collaboration between MNCs and Chinese biotech firms will intensify, driven by the need to address revenue shortfalls from patent expirations [10][14] - The overall improvement in clinical trial data integrity and the increasing number of new molecular entities launched in China are contributing to a more favorable investment landscape [20][22]

Summary of the Conference Call for BeiGene Company Overview - **Company**: BeiGene - **Date**: October 20, 2025 - **Industry**: Biotechnology, specifically focusing on hematology and oncology Key Points and Arguments Financial Performance - **Revenue Guidance**: For 2025, BeiGene's revenue is projected to be between $4.9 billion and $5.3 billion, with an upward adjustment from the initial guidance of $4.9 billion to $5.3 billion made during the mid-year report [3][4] - **Gross Margin**: Expected gross margin is between 80% and 90%, with operating profit remaining positive throughout the year [3][4] Product Performance - **Zebutinib**: - Global sales reached $1.3 billion in 2023, expected to double to $2.6 billion in 2024, and exceed $3.5 billion in 2025, particularly strong growth in the U.S. market [2][6] - Sales in the first half of 2025 reached $1.74 billion, with $1.25 billion from the U.S. alone [6][9] - **PD-1**: - Projected domestic sales of $621 million (approximately 4.5 billion RMB) in 2024, with commercialization in the U.S. starting in October 2025, expected to enhance overseas contributions [2][6] Research and Development Achievements - **R&D Capabilities**: BeiGene has a robust R&D framework, rapidly advancing molecular drugs through global clinical trials, particularly in hematology [4][12] - **Combination Therapies**: The combination of BTK inhibitors with BCL-2 inhibitors and BDKC degraders has shown an overall response rate (ORR) exceeding 90% and a complete response (CR) rate of 70% to 80% [10][11] Strategic Initiatives - **Global Expansion**: Plans to strengthen the global team and optimize sales efficiency through a combination of self-developed products and agency models [5][7] - **Market Listings**: Intent to list on U.S., Hong Kong, and STAR Market to secure funding for ongoing R&D [8][12] Future Development Strategies - **Hematology Focus**: Continued emphasis on blood cancers, with plans for head-to-head clinical trials for new therapies [9][11] - **Solid Tumors**: Initiating Phase III clinical trials for CDK4/6 inhibitors in breast cancer and advancing ADC development to address drug resistance and efficacy issues [12][13] Additional Insights - **Market Dynamics**: The decline in ibrutinib market share due to patent expiration is noted, highlighting the competitive landscape [2][6] - **Patient-Centric Approach**: The company aims to address diverse patient needs through innovative drug development across multiple therapeutic areas [2][4] This summary encapsulates the critical insights from the conference call, focusing on BeiGene's financial outlook, product performance, R&D achievements, strategic initiatives, and future development plans.

Core Viewpoint - BeiGene's stock price has shown significant volatility, with a year-to-date increase of 73.42%, but a recent decline in the short term, indicating potential market fluctuations and investor sentiment changes [1][2]. Group 1: Stock Performance - As of October 20, BeiGene's stock price was 279.24 CNY per share, with a market capitalization of 430.22 billion CNY [1]. - The stock has experienced a 1.73% decline over the last five trading days and an 11.51% decline over the last 20 days, despite a 11.80% increase over the last 60 days [1]. - Year-to-date, the stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) once, with the last appearance on September 2 [1]. Group 2: Financial Performance - For the first half of 2025, BeiGene reported a revenue of 17.518 billion CNY, representing a year-on-year growth of 46.03%, and a net profit of 450 million CNY, which is a 115.63% increase compared to the previous period [2]. - The number of shareholders decreased by 3.90% to 23,300, while the average number of circulating shares per person increased by 4.11% to 4,976 shares [2]. Group 3: Shareholder Composition - As of June 30, 2025, the fourth largest shareholder is 中欧医疗健康混合A, holding 4.8254 million shares, an increase of 1.2436 million shares from the previous period [2]. - 万家优选, the sixth largest shareholder, reduced its holdings by 50% to 3 million shares [2]. - 新进股东, 南方中证500ETF, holds 1.7259 million shares, while 香港中央结算有限公司 has exited the top ten shareholders list [2].

Core Insights - The A-share pharmaceutical sector is showing signs of recovery, with significant inflows into representative ETFs, particularly in the CXO segment, indicating strong buying interest [1][7] - The Hong Kong innovation drug ETF (520880) has been trading at a high premium, reflecting robust buying activity, with over 125 million yuan entering the market for low absorption last week [5][7] - The pharmaceutical sector is experiencing mixed performance, with some stocks like Kelun Pharmaceutical and Baillie Gifford rising over 2%, while others like Pianzihuang faced pressure post-earnings [3][5] Group 1: Market Performance - The A-share medical sector is rebounding, with notable gains in CXO stocks, exemplified by WuXi AppTec's 3% rebound and the largest medical ETF (512170) seeing a peak premium of 1% during trading [1][3] - The only drug ETF in the market (562050) is stabilizing near water level, with frequent premiums observed in the market [3] - The Hong Kong innovation drug ETF (520880) opened over 1% higher but quickly fell below water before recovering, with major stocks like BeiGene rising over 3% while others like CanSino Biologics dropped over 2% [5][7] Group 2: Investment Strategies - Analysts suggest that the innovation drug sector may be entering a configuration window, with multiple catalysts expected in Q4, including major industry conferences and positive Q3 earnings expectations [7] - Investment strategies are focusing on two main lines: identifying stocks with strong Q3 earnings and continuing to explore innovative drugs in preparation for a potential market rebound [7][8] - The Hong Kong innovation drug ETF (520880) is characterized by 100% investment in innovative drug companies, while the largest medical ETF (512170) includes a mix of medical devices and services [8][9]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （前稱BeiGene, Ltd. 百濟神州有限公司） （先前於開曼群島註冊成立的有限公司，並已在瑞士存續註冊） （股份代號：06160） 變更英文公司名稱及英文股份簡稱 本公司於香港聯交所的股份代碼維持不變，仍為「06160」。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年10月17日 變更英文公司名稱 如該公告所披露，公司的英文名稱已由BeiGene, Ltd. 變更為BeOne Medicines Ltd.，自2025年5月27日生效（瑞士時間）。 本公司欣然宣佈，香港公司註冊處處長已於2025年10月2日發出註冊非香港公司 變更名稱註冊證明書，證明BeOne Medicines Ltd.已根據香港法例第622章《公司 條例》第16部在香港註冊為本公司英文名稱。 變更英文股份簡稱 公司英文名稱變更完成後，於香港聯交所進行股 ...

Core Viewpoint - The company BeiGene, Ltd. will change its English name to BeOne Medicines Ltd., effective May 27, 2025 (Swiss time) [1] Group 1 - Following the name change, the English stock trading abbreviation on the Hong Kong Stock Exchange will change from "BEIGENE" to "BEONE MEDICINES," effective from 9:00 AM on October 22, 2025 (Hong Kong time) [1] - The Chinese stock trading abbreviation on the Hong Kong Stock Exchange will remain unchanged as "百济神州" [1]

Core Viewpoint - The company Beigene has completed its name change, and its English stock trading abbreviation on the Hong Kong Stock Exchange will change from "BEIGENE" to "BEONE MEDICINES" effective from October 22, 2025 [1] Group 1 - The English stock trading abbreviation will be updated to reflect the new company name [1] - The Chinese stock trading abbreviation will remain unchanged as "百济神州" [1]

Core Viewpoint - The company Beigene has completed its name change, and its stock trading name on the Hong Kong Stock Exchange will change from "BEIGENE" to "BEONE MEDICINES" effective from October 22, 2025 [1] Company Summary - The English stock trading name change will take effect at 9:00 AM Hong Kong time on October 22, 2025 [1] - The Chinese stock trading name will remain unchanged as "百济神州" [1]